Shares of Horizon Pharma Inc. (NASDAQ:HZNP) have received a consensus recommendation of “Buy” from the sixteen brokerages that are presently covering the firm. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, eleven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $31.70.
A number of research analysts recently weighed in on HZNP shares. Vetr upgraded shares of Horizon Pharma from a “buy” rating to a “strong-buy” rating in a report on Monday, October 3rd. Stifel Nicolaus restated a “buy” rating and issued a $45.00 price objective on shares of Horizon Pharma in a report on Wednesday, July 6th. Guggenheim restated a “buy” rating and issued a $30.00 price objective on shares of Horizon Pharma in a report on Tuesday, August 23rd. Morgan Stanley upgraded shares of Horizon Pharma from an “underweight” rating to an “equal weight” rating and set a $24.00 price objective for the company in a report on Monday, July 11th. Finally, Brean Capital restated a “buy” rating and issued a $30.00 price objective on shares of Horizon Pharma in a report on Thursday, July 14th.
Shares of Horizon Pharma (NASDAQ:HZNP) opened at 18.25 on Friday. The stock’s market cap is $2.94 billion. Horizon Pharma has a 52-week low of $12.86 and a 52-week high of $23.70. The company’s 50-day moving average is $18.92 and its 200-day moving average is $17.86.
Horizon Pharma (NASDAQ:HZNP) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.50 by $0.12. Horizon Pharma had a negative net margin of 0.34% and a positive return on equity of 23.46%. The business earned $257.40 million during the quarter, compared to analysts’ expectations of $235.43 million. During the same period last year, the business earned $0.39 earnings per share. The business’s revenue for the quarter was up 48.9% on a year-over-year basis. Equities analysts anticipate that Horizon Pharma will post $2.15 EPS for the current year.
In related news, EVP Jeffrey W. Sherman sold 2,900 shares of the company’s stock in a transaction on Tuesday, August 2nd. The shares were sold at an average price of $20.00, for a total value of $58,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.10% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the stock. Canada Pension Plan Investment Board acquired a new stake in Horizon Pharma during the first quarter valued at approximately $114,000. Societe Generale acquired a new stake in Horizon Pharma during the second quarter valued at approximately $117,000. SG Americas Securities LLC acquired a new stake in Horizon Pharma during the second quarter valued at approximately $117,000. Nuveen Asset Management LLC purchased a new position in shares of Horizon Pharma during the second quarter worth approximately $176,000. Finally, Profund Advisors LLC purchased a new position in shares of Horizon Pharma during the second quarter worth approximately $194,000. Hedge funds and other institutional investors own 85.25% of the company’s stock.
About Horizon Pharma
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.
Receive News & Ratings for Horizon Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.